Bain Capital Life Sciences Fund II, L.P.

Overview

• HeadquartersBoston, United States²
• Legal formlimited partnership²
• Kind of organizationLimited partnership²
• LEI549300NTNDLALXUXON46²
• StatusActive²
• LEI statusIssued and current²
• Registered addressPO Box 309, KY1-1104 Grand Cayman, Cayman Islands²
• Registered withGeneral Registry, MC-99850²

See how the biggest companies compare on our leaderboards

Corporate structure

Bain Capital Life Sciences Fund II, L.P. sits at the top of its group. 7 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (6 companies). Each entity in the chart links to its source.

Timeline

1. May 22, 2020Founded Bain Capital Life Sciences Fund II, L.P. is founded²

Filings

25 filings to the SEC since October 2021: 25 other. The latest 20:

1. Aug 31, 2026N-PX EDGAR
2. Aug 14, 202613F-NT EDGAR
3. May 15, 202613F-NT EDGAR
4. Feb 17, 202613F-NT EDGAR
5. Nov 14, 202513F-NT EDGAR
6. Aug 29, 2025N-PX EDGAR
7. Aug 14, 202513F-NT EDGAR
8. Jul 24, 2025144 EDGAR
9. May 15, 202513F-NT EDGAR
10. Feb 14, 202513F-NT EDGAR
11. Dec 11, 2024144 EDGAR
12. Nov 14, 202413F-NT EDGAR
13. Aug 30, 2024N-PX EDGAR
14. Aug 12, 202413F-NT EDGAR
15. May 15, 202413F-NT EDGAR
16. Feb 13, 202413F-NT EDGAR
17. Nov 14, 202313F-NT EDGAR
18. Aug 14, 202313F-NT EDGAR
19. May 15, 202313F-NT EDGAR
20. Feb 14, 202313F-NT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

Bain Capital Life Sciences Fund II, L.P. has told the SEC it owns more than 5% of 6 companies, latest first (Schedules 13D and 13G).

• Xilio Therapeutics, Inc.SCHEDULE 13G/A Nov 5, 2021 to May 15, 2026³
• Mersana Therapeutics (United States)SCHEDULE 13D/A Jan 3, 2022 to Jan 8, 2026⁴
• C4 Therapeutics (United States)SCHEDULE 13G Oct 24, 2025⁵
• Savara IncSCHEDULE 13D/A Jul 19, 2023 to Mar 27, 2025⁶
• Syros Pharmaceuticals, Inc.SC 13G/A Feb 14, 2022 to Nov 14, 2024⁷
• Nuvalent, Inc.SC 13D/A Nov 3, 2022 to Mar 29, 2024⁸